Using Ex Vivo Tumoroids To Predict Immunotherapy Response In NSCLC

Recruiting now

Conditions studied: Lung Cancer, NSCLC, NSCLC Stage IV

In brief

To test whether it is feasible to perform the 3D-EX functional predictive response bioassay in the context of patients with advanced/metastatic NSCLC receiving immune checkpoint inhibitors in the standard of care clinical setting.

Key facts

Study ID
NCT05332925
Run by
Jun Zhang, MD, PhD
People needed
25
Starts
2022-07-21
Expected to finish
2027-02-01
Last updated by the study team
2024-02-23

Who can join

Age: 18 and older, up to 110. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.